Showing the single result

• 

  Mantle cell lymphoma

  Ibrutinib

  【Product name】Imbruvica

  [English common name]Ibrutinib

  [Chinese common name]Ibrutinib

  [English name]Ibrutinib N-2, Ibrutinib intermeidate N-2, Ibrutinib INT1

  [Chinese other name]Ibbutinib intermediate N-2, Ibrutinib intermediate, Ibrutinib intermediate N-2

  [Indications] IMBRUVICA is a kinase inhibitor shown for the treatment of patients:
  Who received at least one pre-treatmentMantle cell lymphoma (MCL).
  Accelerate the approval of the overall response rate based on this indicator. This instruction continues to approve the clinical effectiveness validation team without a confirmatory trial.
  Chronic lymphocytic leukemia (CLL).
  Chronic lymphocyte leukemia17p is missing.
  Waldenstrom's macroglobulinemia (WM).

  [Usage and Dosage] MCL: 560 mg, once a day orally (4 capsules of 140 mg once daily).
  CLL and WM: 420 mg once daily (third grade 140 mg capsule once daily).
  Capsules should be taken orally in a glass of water. Do not open, rest, or chew capsules.

  [Storage] Bottles are stored at room temperature between 20 ° C and 25 ° C (68 ° F to 77 ° F). The tour is allowed between 15 ° C and 30 ° C (59 ° F to 86 ° F). Keep the original packaging until dispensing.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.